In a research update to clients today, Kim maintained his “Buy” rating and one-year price target of $5.75 on Firan Technology Group, implying a return of 38 per cent at the time of publication, including dividend.
Kim says despite the fact that he has had numerous upward revisions to his forecasts, he continues to see a company in Firan whose margins are “on the tipping point” of a major inflection that should drive another material uptick in revenue and margins.
“Recent acquisitions (with more to come) and new programs promise to deliver terrific growth, both top line and importantly, bottom line leverage, with 30% EBITDA contribution from acquired assets,” the analyst says. “Emerging still are new programs, new products, growing cross selling opportunities and a potentially massive increase in utilization in the company’s China JV.”
Kim thinks Firan will generate Adjusted EBITDA of $13.5-million on revenue of $105.7-million in fiscal 2017. He expects those numbers will improve to EBITDA of $19.4-million on a topline of $117.8-million the following year.
Haywood Securities analyst Neal Gilmer says lower Canadian cannabis market share is weighing on Tilray Brands (Tilray Brands Stock Quote,… [Read More]
National Bank Financial analyst Baltej Sidhu says Anaergia’s (Anaergia Stock Quote, Chart, News, Analysts, Financials TSX:ANRG) divestiture of two legacy… [Read More]
RBC assistant chief economist Cynthia Leach says the public sector is playing a larger role in Canada’s investment boom than… [Read More]
Research Capital analyst Andre Uddin says Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) reported another strong… [Read More]
Roth Capital Partners analyst Craig Irwin says VersaBank (VersaBank Stock Quote, Chart, News, Analysts, Financials NASDAQ:VBNK) is nearing a potential… [Read More]
Roth Capital Partners analyst Max Masucci says Rapid Micro Biosystems (Rapid Micro Biosystems Stock Quote, Chart, News, Analysts, Financials NASDAQ:RPID)… [Read More]